Valacyclovir for herpes simplex encephalitis
- PMID: 21576427
- PMCID: PMC3122427
- DOI: 10.1128/AAC.01023-10
Valacyclovir for herpes simplex encephalitis
Abstract
The recommended treatment for herpes simplex encephalitis (HSE) remains intravenous acyclovir. In resource-poor countries, however, intravenous formulations are usually unavailable or unaffordable. We report the penetration of acyclovir into the cerebrospinal fluid (CSF) in patients with HSE, treated with the oral prodrug valacyclovir at 1,000 mg three times daily. The oral therapy achieved adequate acyclovir concentrations in the CSF and may be an acceptable early treatment for suspected HSE in resource-limited settings.
Figures
References
-
- Collins P. 1983. The spectrum of antiviral activities of acyclovir in vitro and in vivo. J. Antimicrob. Chemother. 12(Suppl. B):19–27 - PubMed
-
- Crumpacker C. S., Gonzalez R. G., Makar R. S. 2003. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 26-2003. A 50-year-old Colombian man with fever and seizures. N. Engl. J. Med. 349:789–796 - PubMed
-
- Lycke J., Andersen O., Svennerholm B., Appelgren L., Dahlof C. 1989. Acyclovir concentrations in serum and cerebrospinal fluid at steady state. J. Antimicrob. Chemother. 24:947–954 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
